a Novel BioMarker for Diagnosis and Prognosis of Preeclampsia Disorder

Keshet Eli, HUJI, School of Medicine - IMRIC, Developmental Biology and Cancer Research


Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester.

sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclampsia placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia.

Our Innovation

We have developed two antibodies to the human-specific isoform of the gene responsible for Preeclampsia disorder, that was shown to be extremely valuable for diagnosis and prognosis of Preeclampsia. The technology was validated in two cohorts of early and late onset Preeclampsia patient samples were used to measure and evaluate the clinical performance of total sFLT, sFLT1-13 and sFLT1-14. A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in nonendothelial cells.



Patent Status

Granted US 9,797,911

Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: